U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. United States Food and Drug Administration and Health Canada Joint Regional Consultation on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)
  1. Drugs

United States Food and Drug Administration and Health Canada Joint Regional Consultation on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)

United States Food and Drug Administration and Health Canada Joint Regional Consultation on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)

FDA and Health Canada will cohost a regional public meeting entitled ‘‘United States Food and Drug Administration and Health Canada Joint Regional Consultation on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)’’ to provide information and receive comments on the current activities of ICH as well as the upcoming meetings in Charlotte, USA scheduled for November 10 through 15, 2018. The topics for discussion include the current ICH guideline topics under development that will be discussed at the forthcoming ICH Assembly Meeting in Charlotte – see agenda for list of discussion topics. The purpose of this public meeting is to solicit public input prior to the next ICH Assembly meeting and the expert working group meetings in Charlotte.

Date:
October 17, 2018
 
Time:
9:00 a.m. to 12:00 p.m. ET
 
Location:
Sir Frederick G. Banting Research Centre
251 Sir Frederick Banting Dr.
Ottawa, ON K1Y 0M1, Canada

Or

Webcast (A website to access the webcast will be emailed to those who register for the meeting as a remote attendee – see Registrationdisclaimer icon for details)

Registration:

If you wish to attend the public meeting either in-person or via webcast, please register at the following website:  Eventbritedisclaimer icon. Registrations may be limited, so early registration is recommended. Registration is free and will be on a first-come, first-served basis. However, the number of participants from each organization may be limited based on space limitations. Registrants will receive confirmation once they have been accepted.

Contacts:

For more information: please contact William Lewallen, William.Lewallen@fda.hhs.gov